Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6) - Liselore Loverix, Ignace Vergote, Pieter Busschaert, Adriaan Vanderstichele, Bram Boeckx, Tom Venken, Philipp Harter, Hilde Brems, Els Van Nieuwenhuysen, Sandro Pignata, Thaïs Baert, Antonio Gonzalez-Martin, Sileny Han, Christian Marth, Patrick Neven - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, Gynecologic Oncology, (166), p. S51-S52, 2022

DOI: 10.1016/s0090-8258(22)01299-9

Links

Tools

Export citation

Search in Google Scholar

Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)

Journal article published in 2022 by Liselore Loverix, Ignace Vergote, Pieter Busschaert, Adriaan Vanderstichele, Bram Boeckx, Tom Venken, Philipp Harter, Hilde Brems, Els Van Nieuwenhuysen, Sandro Pignata, Thaïs Baert, Antonio Gonzalez-Martin, Sileny Han, Christian Marth, Patrick Neven and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO